Quantinno Capital Management LP Sells 153,541 Shares of Elanco Animal Health Incorporated $ELAN

Quantinno Capital Management LP lowered its position in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 8.4% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,680,427 shares of the company’s stock after selling 153,541 shares during the quarter. Quantinno Capital Management LP’s holdings in Elanco Animal Health were worth $40,213,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. NewEdge Advisors LLC boosted its stake in Elanco Animal Health by 133.7% in the fourth quarter. NewEdge Advisors LLC now owns 1,096 shares of the company’s stock valued at $25,000 after acquiring an additional 627 shares during the last quarter. Root Financial Partners LLC lifted its position in shares of Elanco Animal Health by 50.7% during the fourth quarter. Root Financial Partners LLC now owns 1,759 shares of the company’s stock worth $40,000 after acquiring an additional 592 shares in the last quarter. Uniplan Investment Counsel Inc. bought a new position in Elanco Animal Health in the 4th quarter worth about $41,000. Torren Management LLC bought a new position in shares of Elanco Animal Health in the fourth quarter valued at approximately $46,000. Finally, Bessemer Group Inc. boosted its holdings in Elanco Animal Health by 33.2% in the 1st quarter. Bessemer Group Inc. now owns 2,105 shares of the company’s stock valued at $50,000 after purchasing an additional 525 shares during the period. 97.48% of the stock is owned by hedge funds and other institutional investors.

Elanco Animal Health Trading Up 0.3%

NYSE:ELAN opened at $26.48 on Friday. The company has a market cap of $13.23 billion, a PE ratio of -52.96, a price-to-earnings-growth ratio of 1.72 and a beta of 1.68. The company has a current ratio of 2.16, a quick ratio of 1.12 and a debt-to-equity ratio of 0.60. Elanco Animal Health Incorporated has a 12 month low of $13.39 and a 12 month high of $27.72. The company has a 50 day simple moving average of $24.45 and a two-hundred day simple moving average of $24.06.

Elanco Animal Health (NYSE:ELAN) last posted its earnings results on Wednesday, May 6th. The company reported $0.40 earnings per share for the quarter, beating analysts’ consensus estimates of $0.34 by $0.06. Elanco Animal Health had a positive return on equity of 7.42% and a negative net margin of 4.95%.The company had revenue of $1.37 billion for the quarter, compared to the consensus estimate of $1.28 billion. During the same quarter in the prior year, the company earned $0.37 earnings per share. Elanco Animal Health’s revenue was up 14.9% on a year-over-year basis. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. Research analysts forecast that Elanco Animal Health Incorporated will post 1.11 earnings per share for the current year.

Insider Buying and Selling at Elanco Animal Health

In other news, CEO Jeffrey N. Simmons bought 4,971 shares of the firm’s stock in a transaction on Friday, May 15th. The shares were bought at an average price of $20.09 per share, for a total transaction of $99,867.39. Following the purchase, the chief executive officer owned 171,971 shares in the company, valued at approximately $3,454,897.39. The trade was a 2.98% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Rajeev A. Modi bought 4,911 shares of the stock in a transaction that occurred on Friday, May 15th. The shares were purchased at an average price of $20.35 per share, for a total transaction of $99,938.85. Following the purchase, the insider owned 160,812 shares in the company, valued at $3,272,524.20. This represents a 3.15% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Corporate insiders own 1.14% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on ELAN shares. JPMorgan Chase & Co. boosted their price objective on Elanco Animal Health from $28.00 to $30.00 and gave the stock an “overweight” rating in a report on Thursday, May 7th. TD Cowen raised their price objective on Elanco Animal Health from $31.00 to $32.00 and gave the company a “buy” rating in a research note on Thursday, June 18th. Weiss Ratings cut shares of Elanco Animal Health from a “sell (d+)” rating to a “sell (d)” rating in a research report on Monday, May 11th. Piper Sandler restated an “overweight” rating on shares of Elanco Animal Health in a report on Monday, June 29th. Finally, Citigroup lifted their price target on Elanco Animal Health from $30.00 to $31.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $28.73.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.